Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Irish pharmaceutical firm Actavis has launched a generic version of Fougera's Temovate (clobetasol cream 0.05%), a high-potency corticosteroid, in the US.
Subscribe to our email newsletter
Temovate is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
The launch strengthens the company’s growing portfolio of valuable topical products and shows the deep expertise of its global research and development (R&D) and supply chain capabilities.
According to IMS Health data, for the 12 months ended 15 January 2015, Temovate had total US brand and generic sales of about $185m.
Actavis is focused on developing, manufacturing and commercializing generic, brand, branded generic, legacy brands and over-the-counter (OTC) pharmaceutical products for patients through its more than 30 manufacturing and distribution facilities located around the world.
With commercial operations in more than 60 countries, the company develops medicines for patients suffering from diseases principally in the central nervous system, gastroenterology, women’s health, urology, cardiovascular, respiratory and anti-infective therapeutic categories.